Previous 10 | Next 10 |
Summary Focus still remains on advancing balstilimab, but instead of just using it alone as a monotherapy against advanced cancers, it is being moved forward together with botensilimab. The phase 2 ACTIVATE program will use botensilimab either alone or in combination with balstilimab fo...
Summary Agenus Inc. has been around for decades. Many of its molecules have shown promise. The latest one to do so is Agenus' next-generation anti-CTLA-4 agent botensilimab. A day after I covered Agenus Inc. ( AGEN ) in a positive article on July 4, there was a 20%...
Shares of Agenus (NASDAQ: AGEN) rose 12.5% on Friday. The stock got a bump as investors pounced on a potential bargain when the clinical-stage biopharmaceutical's stock opened at $2.60 a share. One big buyer was Values First Advisors, a financial advisory firm that bought 10,013 shares of...
Searching For The Best Penny Stocks To Buy Now? Take A Look At Unusual Options Activity Do you want to find the best penny stocks to buy this week? While it’s short, there are still plenty of clues to look for if you’re building your watch list. Today we look at clues from...
Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of therapy Patient responses include sarcoma subtypes that historically do not respond to immunotherapy, including responses in 3 of 4...
Searching For The Best Penny Stocks To Buy Now? Take Some Hints From Unusual Options Activity If you’re looking for the best penny stocks to buy right now, you’ve got your work cut out for you. The heightened volatility in the stock market today is some of the wildest we...
LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will ...
Immuno-oncology company Agenus Inc. ( NASDAQ: AGEN ) added ~11% on Monday after announcing data from a Phase 1 study for cancer candidates botensilimab and balstilimab in patients with tumors unresponsive to treatments. The data readout presented at the Society for Immun...
Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS-CRC and advanced melanoma; pancreatic cancer to follow before...
Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q3 2022 Earnings Call Nov 08, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q3 2022 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...